Retatrutide, the peptide assigned the development code LY3437943, works through one mechanism that acts in three places at once. It is a triple receptor agonist, which means a single molecule binds to and activates three separate G-protein-coupled receptors: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Understanding that three-way activity is the whole point of this article, so it stays on the mechanism rather than the background.
For the molecule’s identity, development code, and specifications, see the companion guide on what retatrutide is. Retatrutide research peptides are supplied for laboratory research use only, and everything below describes receptor pharmacology and how the molecule is built. None of it is a statement of approval or a direction for use.
The three receptors it activates
Retatrutide’s mechanism begins with simultaneous agonism at three G-protein-coupled receptors, usually shortened to GPCRs. In the research literature these are the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). A single peptide reaching all three is what earns retatrutide the label triple agonist, or triple-hormone-receptor agonist, and it is the feature that sets it apart from peptides that act on one receptor or two.
The three receptors do related but separate jobs, which is why combining them is of interest to researchers. The GLP-1 receptor is tied to incretin-driven insulin release and to satiety signaling. The GIP receptor is tied to glucose-dependent insulin secretion and to signaling in fat tissue. The glucagon receptor is tied to glucose and lipid handling in the liver and to energy expenditure. Each receptor sits in different tissues, so activating all three at once produces a broader pattern of signaling than any single-receptor agonist can.
How strongly it binds each receptor
The three-way activity is not evenly weighted across the three receptors. In the discovery work by Coskun and colleagues, published in Cell Metabolism in 2022, retatrutide was tested in cAMP assays and behaved as a full agonist at all three human receptors. A full agonist is one that produces the maximum response a receptor can give, rather than a partial one. The measured potencies are shown below.
| Receptor | EC50 (human, cAMP assay) |
|---|---|
| GIP receptor (GIPR) | 0.0643 nM |
| GLP-1 receptor (GLP-1R) | 0.775 nM |
| Glucagon receptor (GCGR) | 5.79 nM |
EC50 is the concentration that produces half of the maximum response, so a lower number means the molecule is more potent at that receptor. Read that way, the numbers place GIP first, GLP-1 second, and glucagon third, a spread of roughly two orders of magnitude between the most and least potent arm.
That order is a deliberate design choice rather than an accident of chemistry. Higher potency at the GIP and GLP-1 receptors, with more modest activity at the glucagon receptor, sets how much each arm contributes and keeps the glucagon effect balanced against the two incretin effects. The hierarchy of GIP over GLP-1 over glucagon comes up again in the sections that follow.
The signaling pathway all three share
For all their differences, the three receptors converge on the same route inside the cell. Each one is coupled to a stimulatory G protein, often written Gs. When retatrutide binds and activates a receptor, that receptor switches on an enzyme called adenylyl cyclase, which sits on the inner face of the cell membrane.
Adenylyl cyclase then raises the level of cyclic AMP, or cAMP, a small second-messenger molecule inside the cell, and cAMP in turn activates protein kinase A. This cAMP cascade is exactly what the potency assays measured, which is why the EC50 values above are described as cAMP potencies rather than binding numbers alone.
The shared pathway is the common signaling language of the mechanism. The same cascade runs behind all three arms, yet because the receptors sit in different tissues, the downstream effect differs from one arm to the next. That combination, one signaling route expressed across several tissues, is what lets a single peptide produce a coordinated metabolic signal.
The GLP-1 receptor arm
The GLP-1 receptor is the anchor of the design and the receptor that single-agonist peptides target on their own. GLP-1 itself is an incretin, a gut hormone released after eating, and its receptor drives glucose-dependent insulin secretion. Glucose-dependent means insulin release is amplified when glucose is elevated, which is the core incretin effect studied across this whole class of molecules.
Beyond the pancreas, the GLP-1 receptor also acts in the brain and along the digestive tract. In the hypothalamus it lowers hunger signaling, and in the gut it slows the rate at which the stomach empties. Taken together, these receptor-level actions are why the GLP-1 arm is treated as the foundation of retatrutide’s mechanism, with the GIP and glucagon arms building on top of it.
The GIP receptor arm
The GIP receptor is where retatrutide is most potent, and it is the same receptor the dual agonist tirzepatide adds to GLP-1 activity. Like GLP-1, GIP is an incretin, and its receptor enhances glucose-stimulated insulin secretion in a glucose-dependent way. That glucose-dependence means the effect scales up when blood sugar is high and does little at normal glucose, a property associated with a lower likelihood of pushing glucose too low.
The GIP receptor is not confined to the pancreas. It is also expressed on white and brown fat cells, where it influences lipid storage, the breakdown of fat, and the release of signaling molecules from fat tissue. The role of GIP in fat tissue is genuinely complex and context-dependent, and whether it is better to agonize or to block the GIP receptor was an open scientific question before dual and triple agonists were put to the test. Retatrutide takes the agonist approach at this receptor.
The glucagon receptor arm
The glucagon receptor is the arm that separates retatrutide from GLP-1-only peptides and from GLP-1-plus-GIP dual agonists. It is expressed mainly in the liver, where it takes part in glucose production and in lipid metabolism. Adding activity at this receptor is the defining idea of the molecule, and it is why retatrutide is classed as a triple rather than a dual agonist.
In diet-induced obese mice, the glucagon-receptor arm of retatrutide was associated with an increase in energy expenditure, a preclinical finding that the discovery work attributed specifically to glucagon-receptor engagement rather than to the incretin arms. Balancing that glucagon activity against the GLP-1 and GIP effects is part of why the potency at the glucagon receptor is set lower than at the other two, as the potency table showed.
Why a single molecule targets three receptors
The rationale for putting three receptor activities into one peptide is that their effects are complementary rather than redundant. For reference, semaglutide is a single GLP-1 agonist and tirzepatide is a dual GLP-1 and GIP agonist. Retatrutide adds glucagon-receptor activity on top of both, which is the step that moves it from the dual category into the triple category.
The three arms are not simply stacked, they are tuned. The potency hierarchy of GIP over GLP-1 over glucagon is set so the arms work together instead of pulling against one another, since unopposed glucagon activity would push in a different metabolic direction than the incretin arms. In the discovery and early-phase research, this simultaneous and balanced engagement of all three receptors was the reason the molecule was studied as a distinct compound rather than as a small variation on existing single- or dual-target peptides.
The molecular basis and half-life
The mechanism is not only about which receptors are engaged, but also about how the molecule is built. Retatrutide is a single peptide of 39 amino acids, and its sequence was engineered to reach the specific binding profile shown earlier at each of the three receptors. Small changes to a peptide’s sequence shift how tightly it binds each receptor, so the potency hierarchy is itself a product of that sequence design.
The molecule also carries a fatty-acid modification attached to the peptide chain. That fatty-acid chain lets retatrutide bind to albumin, an abundant carrier protein in the blood, which slows the molecule’s clearance and gives it a long half-life. Half-life extension by fatty-acid acylation is a common strategy for turning a short-lived peptide into a long-acting one.
The extended half-life is what allowed once-weekly subcutaneous dosing in the clinical trials that studied the compound. Part of the mechanism, then, sits outside the receptor pharmacology entirely, in how the molecule is constructed to persist in circulation long enough to act on those receptors over time.
How the mechanism was established
The receptor pharmacology summarized here rests on primary research rather than secondary summaries. The in vitro potencies, the full-agonist behavior, and the mouse energy-expenditure findings all come from the discovery paper by Coskun and colleagues in Cell Metabolism (2022). The human pharmacokinetics that underpin the half-life and dosing interval were reported by Urva and colleagues in a phase 1b study in The Lancet (2022), and a phase 2 study in obesity was published by Jastreboff and colleagues in the New England Journal of Medicine (2023).
For readers who want to go to the source, the phase 2 trial is available in full from the New England Journal of Medicine, and the phase 1b pharmacokinetic study is indexed on PubMed. Reading the primary literature is the best way to check any figure quoted here, including the receptor potencies in the table.
Research use only
This article is a scientific reference on the mechanism of retatrutide research peptides. It describes receptor activity and molecular design because those explain why the compound is studied. Receptor pharmacology on its own does not establish regulatory approval, medical availability, or any instruction for use, and nothing here should be read as such.
All products are supplied for research and development use only. They are not for human or veterinary use, and they are not intended to diagnose, treat, cure, or prevent any disease. Anyone using this material is responsible for handling it in line with institutional requirements and applicable law.